复发或难治性大B细胞淋巴瘤患者接受CD19嵌合抗原受体T细胞治疗后感染的真实世界分析:来自CIBMTR的研究
该研究基于CIBMTR数据,分析了3350例接受商业化CD19 CAR T细胞治疗的复发或难治性大B细胞淋巴瘤患者,其中2804例接受阿基仑赛、546例接受替沙仑赛。输注后100天内834例(24.9%)发生感染,100天累积感染发生率为22%,感染相关死亡率为1.6%。
要点
- 输注后100天内24.9%的患者发生感染,100天累积感染发生率为22%。
- 细菌、病毒、真菌感染分别见于527例(15.7%)、374例(11.2%)、108例(3.2%)。
- 100天感染相关死亡率为1.6%(95%CI 1.2-2.0),感染是173例(12%)患者的主要死因。
核心结论
- 复发或难治性大B细胞淋巴瘤患者接受CD19 CAR T细胞治疗后感染发生率和感染相关死亡率较高。
- 研究识别了感染高危患者,为制定潜在干预措施以减轻感染、改善CAR T细胞治疗后患者结局提供了线索。
研究设计与样本
- 该研究为基于CIBMTR的真实世界分析,纳入2017年12月至2022年6月期间接受商业化CD19 CAR T细胞治疗的3350例复发或难治性大B细胞淋巴瘤患者。
- 治疗产品包括阿基仑赛(n=2804)和替沙仑赛(n=546)。
主要发现
- 输注后100天内834例(24.9%)发生感染,感染密度为每100患者日0.43,100天累积感染发生率为22%。
- 细菌、病毒、真菌感染分别见于527例(15.7%)、374例(11.2%)、108例(3.2%),对应感染密度分别为每100患者日0.23、0.15、0.04。
- 中位随访24个月后,1482例(44%)死亡,其中感染为主要死因者173例(12%)。
- 100天感染相关死亡率为1.6%(95%CI 1.2-2.0)。
- Karnofsky体能评分≤80、CAR T细胞治疗前有感染史、接受阿基仑赛治疗、重度细胞因子释放综合征(≥3级)、重度免疫效应细胞相关神经毒性综合征(≥3级)的患者感染风险增加。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Infection is increasingly recognized as a significant cause of morbidity and mortality in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) receiving CD19 chimeric antigen receptor (CAR) T-cell therapy. The current study analyzed the natural history, risk factors, and outcomes of infection in 3350 patients with R/R LBCL receiving commercial CD19 CAR T-cell therapy (n = 2804 axicabtagene ciloleucel [axi-cel], n = 546 tisagenlecleucel) from December 2017 to June 2022. Infection developed in 834 patients (24.9%) within 100 days after infusion, resulting in an infection density of 0.43 per 100 patient days and a 100-day cumulative incidence of 22%. Bacterial, viral, and fungal infections were recorded in 527 (15.7%), 374 (11.2%), and 108 patients (3.2%), respectively, with corresponding infection densities of 0.23, 0.15, and 0.04 per 100 patient days. After a 24-month median follow-up, 1482 patients (44%) had died, with infection as the primary cause in 173 cases (12%). The 100-day infection-related mortality (IRM) was 1.6% (95% confidence interval, 1.2-2.0). Patients with a Karnofsky performance score of ≤80, infection history before CAR T-cell therapy, axi-cel therapy, severe cytokine release syndrome (grade ≥3), and severe immune effector cell-associated neurotoxicity syndrome (grade ≥3) had increased infection risk. Infections within 100 days were an independent risk factor for inferior overall survival beyond day 100 after CD19 CAR T-cell therapy. In conclusion, study results show a significant incidence of infection and IRM in patients with R/R LBCL treated with CD19 CAR T-cell therapy. Furthermore, results identify patients at a heightened risk of infection, offering insights to guide potential interventions aimed at mitigating infection and improving patient outcomes after CAR T-cell therapy.
引用
- Wudhikarn K, Herr MM, Chen M, et al. Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR. Blood Adv. 2025. PMID: 40435511. doi:10.1182/bloodadvances.2025016141
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。